24 completed, 22 recruiting, 18 terminated, 13 active not recruiting. 43 Phase 2, 32 Phase 1, 13 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Urothelial Cancer: new trials by email Literature Review of Urothelial Cancer trials Research Report on Urothelial Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Tucatinib Continuation Study tucatinib - HER2-positive Breast Cancer, Cervical Cancer | Phase 4 | Not yet recruiting | Pfizer | 175 | 2026-11-06 | 2026-08-28 |
| A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies Metastatic Urothelial Carcinoma, Urothelial Cancer | Not yet recruiting | Pfizer | 5122 | 2026-10-21 | 2026-10-27 | |
| A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] Dato-DXd, Enfortumab Vedotin (EV), Pembrolizumab - Urothelial Cancer, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 268 | 2026-10-16 | 2026-10-22 |
| Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy Acupuncture, Exercise - Metastatic Bladder Cancer, Peripheral Neuropathy | Not applicable | Recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-03 | 2026-10-26 |
| A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers CT-202 - Triple Negative Breast Cancer (TNBC), Colorectal Cancer | Phase 1 | Recruiting | Context Therapeutics Inc. | 162 | 2026-09-01 | 2026-10-08 |
| A Study of MGC030 in Participants With Advanced Solid Tumors MGC030 - Urothelial Cancer, GastroEsophageal Cancer | Phase 1 | Not yet recruiting | MacroGenics | 314 | 2026-09-01 | 2026-09-16 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma Urothelial Cancer, MIBC | Recruiting | Comprehensive Cancer Center Munich (CCCM) | 79 | 2026-06-01 | 2026-10-13 | |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy - Urothelial Cancer, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 390 | 2026-05-11 | 2026-10-19 |
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer PF-08634404, Enfortumab Vedotin - Urothelial Cancer, Advanced/Metastatic Urothelial Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 132 | 2026-03-11 | 2026-10-08 |
| SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel) - Urinary Bladder Cancer, Upper Tract Urothelial Cancer | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 28 | 2026-03-06 | 2026-05-06 |
| A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer Metastatic Urothelial Carcinoma, Urothelial Cancer | Completed | Pfizer | 1 | 2026-02-12 | 2026-05-28 | |
| International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC Locally Advanced or Metastatic Urothelial Cancer, Urothelial Cancer | Not yet recruiting | Aron Research Foundation Ets | 361 | 2026-02-01 | 2026-02-19 | |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer STRO-004, Pembrolizumab - Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC | Phase 1 | Recruiting | Sutro Biopharma, Inc. | 200 | 2025-11-07 | 2026-08-27 |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 355 | 2025-10-02 | 2026-10-05 |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Iza-bren, Cisplatin, Gemcitabine - Urothelial Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 470 | 2025-09-30 | 2026-07-29 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Dato-DXd, Carboplatin, Cisplatin - Urothelial Cancer, Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 630 | 2025-09-26 | 2026-08-20 |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) AVZO-1418, Combination Agent 1, Combination Agent 2 - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 480 | 2025-06-04 | 2026-10-16 |
Showing 20 of 85. Sign in to see all of them.
Urinary Bladder Neoplasms (31) · Carcinoma, Non-Small-Cell Lung (14) · Carcinoma, Transitional Cell (14) · Stomach Neoplasms (11) · Neoplasm Metastasis (10) · Neoplasms (10) · Colorectal Neoplasms (9) · Melanoma (9) · Carcinoma, Renal Cell (7) · Ovarian Neoplasms (7) · Endometrial Neoplasms (6) · Lung Neoplasms (6) · Pancreatic Neoplasms (6) · Triple Negative Breast Neoplasms (6) · Breast Neoplasms (5)
Neoplasms (55) · Neoplasms by Site (55) · Urogenital Diseases (46) · Female Urogenital Diseases and Pregnancy Complications (45) · Female Urogenital Diseases (44) · Urogenital Neoplasms (43) · Male Urogenital Diseases (38) · Urologic Diseases (37) · Urologic Neoplasms (33) · Neoplasms by Histologic Type (32) · Urinary Bladder Diseases (31) · Neoplasms, Glandular and Epithelial (29) · Carcinoma (27) · Digestive System Diseases (20) · Digestive System Neoplasms (20)
pembrolizumab (14) · Gemcitabine (13) · Cisplatin (12) · Carboplatin (9) · enfortumab vedotin (9) · avelumab (5) · Docetaxel (4) · Nivolumab (4) · Paclitaxel (4) · durvalumab (4) · vinflunine (3) · Axitinib (2) · Bevacizumab (2) · Fluorouracil (2) · Ipilimumab (2)
Pfizer (11) · National Cancer Institute (NCI) (6) · Astellas Pharma Global Development, Inc. (4) · Janssen Research & Development, LLC (3) · University of Michigan Rogel Cancer Center (3) · AstraZeneca (2) · Avenzo Therapeutics, Inc. (2) · Bristol-Myers Squibb (2) · Comprehensive Cancer Center Munich (CCCM) (2) · Daiichi Sankyo (2) · Dana-Farber Cancer Institute (2) · Incyte Corporation (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · AHS Cancer Control Alberta (1)
United States (60) · Spain (25) · Italy (22) · South Korea (19) · France (18) · Germany (18) · United Kingdom (18) · Canada (17) · Taiwan (17) · Australia (16) · Japan (16) · Belgium (11) · China (11) · Israel (10) · Netherlands (10)
Andrea B Apolo, M.D. (3) · Ajjai S. Alva, M.D. (2) · Albert Font, MD (1) · Andrea Necchi, Dr. (1) · Anish Thomas, M.D. (1) · Aurelie Garant (1) · Bradley A McGregor, MD (1) · Changting Meng, MD (1) · Christina Dieli-Conwright, PhD, MPH (1)
PMID 31395089, PMID 35247908, PMID 36041086, PMID 36494006, PMID 23228446, PMID 24318901, PMID 25457633, PMID 26454620, PMID 28212060, PMID 28967485, PMID 29562804, PMID 29590008, PMID 31050707, PMID 31340094, PMID 31356140, PMID 32552471, PMID 32622884, PMID 32897402, PMID 32940628, PMID 32945632, PMID 32971005, PMID 33577729, PMID 33986123, PMID 33991512, PMID 34893775, PMID 34951522, PMID 34973108, PMID 34977972, PMID 35030333, PMID 35101941, PMID 35168844, PMID 35176457, PMID 35416053, PMID 35654659, PMID 36652354, PMID 36822667, PMID 37019764, PMID 37071838, PMID 37121850, PMID 37141847, PMID 37149458, PMID 37369081, PMID 37699333, PMID 37870920, PMID 37870949, PMID 37871703, PMID 37884606, PMID 37972659, PMID 38215355, PMID 38418343
2017 (8), 2023 (4), 2014 (3), 2015 (2), 2016 (2), 2025 (2), 2008 (1), 2019 (1)